{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-068589","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.952483+00:00","generated_at":"2026-05-31T09:17:11.029139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M","bullets":["Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.","DefenCath net sales $0.8M for partial quarter since April 15 inpatient launch; outpatient QTD sales $5.2M as of Aug 13.","Operating expenses $15.6M in Q2 (+32% YoY) from commercial launch costs; R&D down 86% post-approval.","Cash and short-term investments $45.6M at June 30, sufficient for at least 12 months.","Submitted TPN study protocol to FDA; patient enrollment expected to begin Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-068589","json":"https://secwatch.observer/filing/0001213900-24-068589.json","markdown":"https://secwatch.observer/filing/0001213900-24-068589.md","text":"https://secwatch.observer/filing/0001213900-24-068589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024068589/0001213900-24-068589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390024068589/ea0211338-8k_cormed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:11.029139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}